
Regeneron Pharmaceuticals, Inc.
REGN·NASDAQ
Last updated as of 2026-05-15 09:55 EST. Stock price information is sourced from TradingView and reflects real-time market prices.
Insights
Calculator
News
REGN stock price change
On the last trading day, REGN stock closed at 719.88 USD, with a price change of -0.49% for the day.
Trade stock perpsTrending stocks
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreREGN key data
Previous close719.88 USD
Market cap75.47B USD
Volume879.25K
P/E ratio17.54
Dividend yield (TTM)0.49%
Dividend amount0.94 USD
Last ex-dividend dateFeb 20, 2026
Last payment dateMar 05, 2026
EPS diluted (TTM)41.04 USD
Net income (FY)4.50B USD
Revenue (FY)14.34B USD
Next report dateJul 30, 2026
EPS estimate10.850 USD
Revenue estimate3.81B USD USD
Shares float100.91M
Beta (1Y)0.59

Regeneron Pharmaceuticals, Inc. overview
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
regeneron.com
Founded
1988
Employees (FY)
15.41K
Change (1Y)
+304 +2.01%
Revenue / Employee (1Y)
930.75K USD
Net income / Employee (1Y)
292.34K USD
REGN Pulse
Daily updates on REGN stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.
See more
about 21h ago
See more
about 1D ago
REGN stock price forecast
According to technical indicators for REGN stock, the price is likely to fluctuate within the range of 762.66–950.22 USD over the next week. Market analysts predict that the price of REGN stock will likely fluctuate within the range of 699.12–984.75 USD over the next months.
Based on 1-year price forecasts from 51 analysts, the highest estimate is 1335.41 USD, while the lowest estimate is 742.99 USD.
For more information, please see the
REGN stock price forecast
page.
Latest REGN stock news
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss
Finviz2026-03-10 02:42:44
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
Finviz2026-03-10 10:37:05
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Finviz2026-03-11 23:24:50
The U.S. Food and Drug Administration (FDA) has officially approved Regeneron Pharmaceuticals' Eylea HD for the treatment of a rare pediatric disease.
老虎证券2026-03-12 13:25:01
CytomX's Varsetatug Masetecan (EpCAM PROBODY ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
Finviz2026-03-16 11:03:45
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-16 20:09:45
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-16 20:09:45
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-18 02:52:13
A record $5.7 trillion “Quadruple Witching Day” looms over U.S. stocks! As Middle East conflict escalates, a volatility storm is about to erupt
金融界2026-03-20 01:11:52
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
Finviz2026-03-24 10:48:48
EYLEA HD (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
Finviz2026-04-02 16:03:43
The U.S. Food and Drug Administration (FDA) has officially approved Regeneron Pharmaceuticals' Eylea HD® (Aflibercept) for market release.
老虎证券2026-04-02 16:16:15
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Finviz2026-04-02 20:33:45
Regeneron Pharmaceuticals announced that, as part of their strategic partnership, the company will invest up to 200 million dollars in Trinetx.
老虎证券2026-04-02 20:53:01
Regeneron Pharmaceuticals has announced it will lower the pricing of its drugs under the Medicaid program and plans to align drug prices in the US market with those in other countries in the future.
老虎证券2026-04-23 19:59:03
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss
Finviz2026-03-10 02:42:44
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
Finviz2026-03-10 10:37:05
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
Finviz2026-03-11 23:24:50
The U.S. Food and Drug Administration (FDA) has officially approved Regeneron Pharmaceuticals' Eylea HD for the treatment of a rare pediatric disease.
老虎证券2026-03-12 13:25:01
CytomX's Varsetatug Masetecan (EpCAM PROBODY ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
Finviz2026-03-16 11:03:45
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Finviz2026-03-16 20:09:45

